Gene News and Research

Latest Gene News and Research

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Researchers update 'Hallmarks of Cancer' seminal review

Renowned cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

17 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

17 Mar 2011

Bacteria more likely to adopt 'loner' genes

A new study of more than three dozen bacteria species - including the microbes responsible for pneumonia, meningitis, stomach ulcers and plague - settles a longstanding debate about why bacteria are more likely to steal some genes than others.

17 Mar 2011

Skyline Diagnostics launches unique test to detect patients with AML

Each year over eight million people die of cancer worldwide. Patients' chances of survival vary widely: depending on the type of cancer involved, the stage at which it is diagnosed and the speed with which appropriate treatment is launched.

17 Mar 2011

Pig model reveals how cystic fibrosis gene mutation causes disease

It's been more than 20 years since scientists first discovered the gene that causes cystic fibrosis (CF), yet questions about how the mutated gene causes disease remain unanswered.

17 Mar 2011

Naltrexone may be effective in women with specific genetic variation

Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary results show that naltrexone, one of the only medications approved for treating people with alcohol abuse problems, may only be effective in women and those with a specific genetic variation.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling.

16 Mar 2011

TESE offers fertility to male cancer survivors

An intricate procedure that finds and carefully removes individual sperm from testicular tissue has made fathers of men who were once considered sterile due to prior cancer treatment, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center who pioneered the technique.

16 Mar 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

Genomatix launches service model for NGS data analysis

The growing amount of data created by today's high throughput DNA sequencing technology presents a major challenge to scientists around the globe. How to handle the staggering amount of data, and, more importantly, how to answer the biological questions that initiated the experiment?

16 Mar 2011

Manchester research offers hope for congenital hyperinsulinism treatment

University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.

16 Mar 2011

Researchers identify genetic cause of magnesium deficiency

Researchers and scientists of the Charité - Universitätsmedizin Berlin, in cooperation with the Max Delbrück Center for Molecular Medicine, and colleagues from the Netherlands, Belgium, Switzerland and the Czech Republic have succeeded in identifying a genetic cause of magnesium deficiency.

16 Mar 2011

Global settlement agreement reached in Tuschl patents litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.

16 Mar 2011

Gene News and Research

Latest Gene News and Research

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Researchers update 'Hallmarks of Cancer' seminal review

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

Gene therapy holds promise for Parkinson's treatment

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

Bacteria more likely to adopt 'loner' genes

Skyline Diagnostics launches unique test to detect patients with AML

Pig model reveals how cystic fibrosis gene mutation causes disease

Naltrexone may be effective in women with specific genetic variation

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

TESE offers fertility to male cancer survivors

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Genomatix launches service model for NGS data analysis

Manchester research offers hope for congenital hyperinsulinism treatment

Researchers identify genetic cause of magnesium deficiency

Global settlement agreement reached in Tuschl patents litigation

BRAF gene defect leads to pilocytic astrocytoma in children

Researchers discover molecular switch for insulin secretion

March of Dimes to honor fragile X syndrome researcher with Lifetime Achievement award

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production